Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:vaccine
|
| gptkbp:administeredBy |
injection
|
| gptkbp:age |
children and adults
|
| gptkbp:approvedBy |
several countries
|
| gptkbp:broadcastOn |
multiple doses
|
| gptkbp:contraindication |
individuals with no prior dengue infection (for Dengvaxia)
|
| gptkbp:developedBy |
gptkb:Sanofi_Pasteur
gptkb:Takeda_Pharmaceutical_Company |
| gptkbp:example |
gptkb:Dengvaxia
gptkb:Qdenga |
| gptkbp:indication |
individuals living in dengue-endemic areas
|
| gptkbp:mechanismOfAction |
induces immune response against dengue virus serotypes 1, 2, 3, and 4
|
| gptkbp:routeOfAdministration |
intramuscular
|
| gptkbp:target |
all four dengue virus serotypes
|
| gptkbp:usedFor |
prevention of dengue fever
|
| gptkbp:WHOStatus |
prequalified
|
| gptkbp:bfsParent |
gptkb:DENVax
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
tetravalent dengue vaccine
|